---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-023459"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2024-02-05T23:59:59+00:00"
generated_at: "2026-06-06T09:13:23.254961+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pliant reports positive Phase 2a data for bexotegrast 320 mg in PSC; fibrosis markers improved

## Summary
- Bexotegrast 320 mg well tolerated with no drug-related severe or serious adverse events; 96% of 27 patients completed 12 weeks.
- Reduced ELF and PRO-C3 levels relative to placebo at Week 12, indicating antifibrotic activity.
- Stabilized alkaline phosphatase and showed improved hepatocyte function and bile flow on contrast MRI vs placebo.
- Statistically significant reduction in itch Numerical Rating Scale at Week 12 for the 320 mg dose.
- Company plans to share data with regulatory authorities to discuss potential registration path.

## SEC filing metadata
- accession: 0001193125-24-023459
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2024-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000119312524023459/0001193125-24-023459-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000119312524023459/d734141d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-023459
- JSON: https://secwatch.observer/filing/0001193125-24-023459.json
- Plain text: https://secwatch.observer/filing/0001193125-24-023459.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.